Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Development of quality indicators for non-small cell lung cancer care: a first step toward assessing and improving quality of cancer care in China

Authors: Xinyu Wang, Shaofei Su, Shouyi Li, Han Bao, Meiqi Zhang, Dan Liu, Hao Jiang, Jiaying Wang, Meina Liu

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Large gap exists between clinical practice and recommended care and large room exists for the improvement of care quality for non-small cell lung cancer (NSCLC) in China. Results of some studies have shown that assessment of care quality can help to make improvement and the development of quality indicators is deemed as the initial and most essential part. Yet there is no such an indicators system specifically suitable for Chinese health care system. The goal of the study is to set up a group of Chinese quality indicators for NSCLC care and make it the first step towards the improvement of NSCLC care quality in China.

Methods

We constructed a new indicator framework based on the characteristics of NSCLC care and the nature of Chinese health care system. Under the new framework, potential indicators were collected and a 3-round modified Delphi process was conducted by a national multi-disciplinary Expert Panel to develop a set of indicators until they reached the final consensus.

Results

A new indicator framework (structure, process, communication, management of symptoms or treatment toxicity and outcome) was developed. Seventy four indicators were extracted from guidelines and relevant literatures as potential indicators; 43 indicators plus 1 suggested indicator were remained after the discussion of Round 1; questionnaires of Round 2 were rated by Expert Panel and 19 indicators met the inclusion criteria and entered Round 3; 2 of the eliminated indicators in Round 2 were retrieved by the Expert Panel at the in-person meeting (Round 3). Therefore, 21 indicators got the final consensus of the Expert Panel.

Conclusions

Guided by the new indicator structure, a set of indicators suitable for Chinese healthcare system was developed and can be utilized to measure and improve the care quality of non-small cell lung cancer.
Appendix
Available only for authorised users
Literature
1.
Mazzone PJ, Anil V, Andrew C, Frank D, David C, John H, Amos D, Douglas A. Quality indicators for the evaluation of patients with lung cancer. Chest. 2014;146(3):659–69.CrossRefPubMedPubMedCentral
2.
Ben Amar J, Ben Safta B, Zaibi H, Dhahri B, Baccar MA, Azzabi S. Prognostic factors of advanced stage non-small-cell lung cancer. La Tunisie medicale. 2016;94(5):360–7.PubMed
3.
Sacco PC, Casaluce F, Sgambato A, Rossi A, Maione P, Palazzolo G, Napolitano A, Gridelli C. Current challenges of lung cancer care in an aging population. Expert Rev Anticancer Ther. 2015;15(12):1419–29.CrossRefPubMed
4.
Tawee T, Michelle C, Ji-Hyun L, Fulp WJ, Fred S, Brown RH, Levine RM, Cartwright TH, Guillermo AT, Kim GP. Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in Florida. J. Oncol. Pract. 2011;7(6):e25–31.CrossRef
5.
Chinese Association of Oncologists, Chinese Society for Clinical Cancer Chemotherapy. The Guideline for Diagnosis and Treatment of Chinese Patients with sensitizing EGFR Mutation or ALK Fusion Gene-Positive Non-Small Cell Lung Cancer (2015 Version)[J]. Chin J Oncol. 2015;37(10):796–99.
6.
Rodrigues G, Choy H, Bradley J, Rosenzweig KE, Bogart J, Curran WJ Jr, Gore E, Langer C, Louie AV, Lutz S, et al. Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol. 2015;5(3):141–8.CrossRefPubMed
7.
Shijie J, Huimin F, Wei L, Min X, Luping L, Xiangying A, Chun L, Qian G. Level and Trend of Cancer Mortality in China, 2002-2011. China Cancer. 2014;12:999–1004.
8.
Mainz J. Defining and classifying clinical indicators for quality improvement. Int J Qual Health Care. 2003;15(6):523–30.CrossRefPubMed
9.
Institute of Medicine Committee to Design a Strategy for Quality R, Assurance in M. In: Lohr KN, editor. Medicare: A Strategy for Quality Assurance: VOLUME II Sources and Methods. Washington: National Academies Press (US) Copyright 1990 by the National Academy of Sciences; 1990.
10.
Bryant J, Boyes A, Jones K, Sanson-Fisher R, Carey M, Fry R. Examining and addressing evidence-practice gaps in cancer care: a systematic review. Implement Sci. 2014;9(2):1–7.
11.
Samson P, Crabtree T, Broderick S, et al. Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival[J]. Ann Thorac Surg. 2017;103(1):303–11.
12.
Duggan KJ, Descallar J, Vinod SK. Application of Guideline Recommended Treatment in Routine Clinical Practice: A Population-based Study of Stage I-IIIB Non-small Cell Lung Cancer. Clin Oncol (R Coll Radiol). 2016;28(10):639–47.CrossRef
13.
Chien CR, Tsai CM, Tang ST, Chung KP, Chiu CH, Lai MS. Quality of care for lung cancer in Taiwan: a pattern of care based on core measures in the Taiwan Cancer Database registry. J Formos Med Assoc. 2008;107(8):635–43.CrossRefPubMed
14.
Chien CR, Lai MS. Trends in the Pattern of Care for Lung Cancer and Their Correlation With New Clinical Evidence: Experiences in a University-Affiliated Medical Center. Am J Med Qual. 2006;21(6):408–14.CrossRefPubMed
15.
Potosky AL, Scott S, Wallace RB, Lynch CF. Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol. 2004;22(16):3261–8.CrossRefPubMed
16.
Younis T, Al-Fayea T, Virik K, Morzycki W, Saint-Jacques N. Adjuvant chemotherapy uptake in non-small cell lung cancer. J Thorac Oncol. 2008;3(11):1272–8.CrossRefPubMed
17.
Mccullough ML, Patel AV, Kushi LH, Patel R, Willett WC, Doyle C, Thun MJ, Gapstur SM. Following cancer prevention guidelines reduces risk of cancer, cardiovascular disease, and all-cause mortality. Cancer Epidemiol Biomark Prev. 2011;20(6):1089–97.CrossRef
18.
Michel K, Pablo L, Nancy H, José Ramon GJ, Van Veldhuisen DJ, Erland E, Luigi T, Philip PW, Claude LP. Adherence to Guidelines Is a Predictor of Outcome in Chronic Heart Failure: The MAHLER Survey. ACC Curr J Rev. 2005;14(2):24–5.CrossRef
19.
Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FAR, Moriarty AT, Waxman AG, Wilbur DC. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J. Clin. 2012;62
20.
Shapiro DW, Lasker RD, Bindman AB, Lee PR. Containing costs while improving quality of care: the role of profiling and practice guidelines. Annu Rev Public Health. 1993;14(1):219–41.CrossRefPubMed
21.
Io M, Board NRCNCP. Ensuring Quality Cancer Care: National Academies Press; 1999.
22.
Donabedian A. The Quality of Care: How Can It Be Assessed? J Am Med Assoc. 1988;260(12):1743.CrossRef
23.
Listed N. Characteristics of clinical indicators[J]. Qrb Qual Rev Bull. 1989;15(11):330–39.
24.
Evans WK, Ung YC, Nathalie A, Anna C, Carol S. Improving the quality of lung cancer care in Ontario: the lung cancer disease pathway initiative. J Thorac Oncol. 2013;8(7):876–82.CrossRefPubMed
25.
Hermens RPMG, Ouwens MMTJ, Vonk-Okhuijsen SY, Wel YVD, Tjan-Heijnen VCG, Broek LDVD, Ho VKY, Janssen-Heijnen MLG, Groen HJM, Grol RPTM. Development of quality indicators for diagnosis and treatment of patients with non-small cell lung cancer: A first step toward implementing a multidisciplinary, evidence-based guideline. Lung Cancer. 2006;54(1):117–24.CrossRefPubMed
26.
Lennes IT, Lynch TJ. Quality indicators in cancer care: development and implementation for improved health outcomes in non-small-cell lung cancer. Clin. Lung Cancer. 2009;10(5):341–6.CrossRefPubMed
27.
Brook RH, Mcglynn EA, Shekelle PG. Defining and measuring quality of care: a perspective from US researchers. Int J Qual Health Care. 2000;12(4):281–95.CrossRefPubMed
28.
Wasif N, Cormier JN, Ko CY, Mccahill LE, Edge SB, Wong SL, Anthony T, Kollmorgen D, Marcus SG, Bleznak A. Quality Measurement in Cancer Care Delivery. Ann Surg Oncol. 2011;18(3):611–8.CrossRefPubMed
29.
Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AKP, Govindan R. NCCN Clinical Practice Guidelines in Oncology™ Non-Small Cell Lung Cancer. J. Natl. Compr. Cancer Netw. 2012;10
30.
Ouwens MM, Hermens RR, Termeer RA, Vonk-Okhuijsen SY, Tjan-Heijnen VC, Verhagen AF, Hulscher MM, Marres HA, Wollersheim HC, Grol RP. Quality of integrated care for patients with nonsmall cell lung cancer: variations and determinants of care. Cancer. 2007;110(8):1782–90.CrossRefPubMed
31.
Demartino JK. Measuring Quality in Oncology: Challenges and Opportunities. J Natl Compr Cancer Netw. 2013;11(12):1482–91.CrossRef
32.
Bao H, Yang F, Wang X, Su S, Liu D, Fu R, Zhang H, Liu M. Developing a set of quality indicators for breast cancer care in China. Int J Qual Health Care. 2015;27(4):291–6.CrossRefPubMed
33.
Gagliardi AR, Fung MFK, Langer B. Development of ovarian cancer surgery quality indicators using a modified Delphi approach - Gynecologic Oncology. Gynecol Oncol. 2005;97(6):446–56.CrossRefPubMed
34.
Gagliardi AR, Marko S, Bernard L, Hartley S, Brown AD: Development of quality indicators for colorectal cancer surgery, using a 3-step modified Delphi approach. Can J Surg 2005, 48(6).
35.
Gail D, Richard M, John D, Leigh MK, Cindy N, Amber H, Mcleod RS. Quality indicators for non-small cell lung cancer operations with use of a modified Delphi consensus process. Ann Thorac Surg. 2014;98(1):183–90.CrossRef
36.
Jakobsen E, Green A, Oesterlind K, Rasmussen TR, Iachina M, Palshof T. Nationwide quality improvement in lung cancer care: the role of the Danish Lung Cancer Group and Registry. J Thorac Oncol. 2013;8(10):1238–47.CrossRefPubMed
37.
Jan M, Anne-Marie H, Torben P, Bartels PD. National quality measurement using clinical indicators: the Danish National Indicator Project. J Surg Oncol. 2009;99(8):500–4.CrossRef
Metadata
Title
Development of quality indicators for non-small cell lung cancer care: a first step toward assessing and improving quality of cancer care in China
Authors
Xinyu Wang
Shaofei Su
Shouyi Li
Han Bao
Meiqi Zhang
Dan Liu
Hao Jiang
Jiaying Wang
Meina Liu
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3602-0

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer

Research article

The tumor suppressor RhoBTB1 controls Golgi integrity and breast cancer cell invasion through METTL7B

Research article

The IGCA staging system is more accurate than AJCC7 system in stratifying survival of patients with gastric cancer in stage III

Research article

Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients

Research article

High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer

Study protocol

Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits